Nyrada Inc – Phase I Clinical Trial Dosing Update #3

Highlights:
•Safety Review Committee (SRC) for Nyrada’s Phase I clinical trial has considered cumulative safety and pharmacokinetic data, including from the third dosed cohort.
•SRC raised no issues, enabling the clinical trial to proceed to the next cohort.